{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:54:04Z","timestamp":1794668044046,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer\u2019s Drug Discovery Foundation","doi-asserted-by":"publisher","award":["WNCN-P40813; WNCN-P62411"],"award-info":[{"award-number":["WNCN-P40813; WNCN-P62411"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer\u2019s disease syndrome. \u2018Evaluating liraglutide in Alzheimer\u2019s disease\u2019 (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer\u2019s disease syndrome with no diabetes. Participants received daily injections of liraglutide or placebo for 52\u2009weeks. They underwent fluorodeoxyglucose positron emission tomography, magnetic resonance imaging and detailed neuropsychometric evaluations. The primary outcome was a change in cerebral glucose metabolic rate. Secondary outcomes were safety and tolerability and cognitive changes. The primary outcome showed no significant differences in cerebral glucose metabolism (difference\u2009=\u2009\u22120.17; 95% confidence interval: \u22120.39 to 0.06;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.14) between the two groups. The secondary outcome\u2014score on the Alzheimer\u2019s Disease Assessment Scale-Executive domain (ADAS-Exec)\u2014performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03\u22120.28; unadjusted\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). No significant differences were observed in Alzheimer\u2019s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (\u22120.58; 95% confidence interval: \u22123.13 to 1.97; unadjusted\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.65) or Clinical Dementia Rating-Sum of Boxes (CDR-SoB) (\u22120.06; 95% confidence interval: \u22120.57 to 0.44; unadjusted\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.81) scores. Liraglutide was generally safe and well tolerated in non-diabetic patients with Alzheimer\u2019s disease. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/study\/NCT01843075\" ext-link-type=\"uri\">NCT01843075<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04106-7","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:02:54Z","timestamp":1764583374000},"page":"353-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-2002","authenticated-orcid":false,"given":"Paul","family":"Edison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Daniela","family":"Femminella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-8200","authenticated-orcid":false,"given":"Zuzana","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Ridha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanara","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Mcfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Coulthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-9487","authenticated-orcid":false,"given":"Benjamin R.","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koranteng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Prasanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-183X","authenticated-orcid":false,"given":"Ramin","family":"Nilforooshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Macharouthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghma","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Mate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Kshemendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-3260","authenticated-orcid":false,"given":"Christian","family":"Holscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mae","family":"Chester-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-3432","authenticated-orcid":false,"given":"Trisha","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-1941","authenticated-orcid":false,"given":"Steve","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhaar","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-4923","authenticated-orcid":false,"given":"John","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-9207","authenticated-orcid":false,"given":"Rainer","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Peter","family":"Passmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"4106_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","volume":"20","author":"VR Aroda","year":"2018","unstructured":"Aroda, V. R. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes. Metab. 20, 22\u201333 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"4106_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","volume":"783","author":"L Qi","year":"2016","unstructured":"Qi, L. et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced alzheimer disease mouse model. Eur. J. Pharmacol. 783, 23\u201332 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"4106_CR3","first-page":"2449","volume":"18","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Liraglutide improves cognitive impairment via the AMPK and PI3K\/Akt signaling pathways in type 2 diabetic rats. Mol. Med. Rep. 18, 2449\u20132457 (2018).","journal-title":"Mol. Med. Rep."},{"key":"4106_CR4","doi-asserted-by":"crossref","unstructured":"Duarte, A. I. et al. Liraglutide protects against brain amyloid-\u03b21\u221242 accumulation in female mice with early Alzheimer\u2019s disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation. Int. J. Mol. Sci. 21, 1746 (2020).","DOI":"10.3390\/ijms21051746"},{"key":"4106_CR5","doi-asserted-by":"crossref","first-page":"e58784","DOI":"10.1371\/journal.pone.0058784","volume":"8","author":"V Parthsarathy","year":"2013","unstructured":"Parthsarathy, V. & Holscher, C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS ONE 8, e58784 (2013).","journal-title":"PLoS ONE"},{"key":"4106_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","volume":"293","author":"PL McClean","year":"2015","unstructured":"McClean, P. L., Jalewa, J. & Holscher, C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice. Behav. Brain Res. 293, 96\u2013106 (2015).","journal-title":"Behav. Brain Res."},{"key":"4106_CR7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","volume":"46","author":"HH Hansen","year":"2015","unstructured":"Hansen, H. H. et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s disease. J. Alzheimers Dis. 46, 877\u2013888 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"4106_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"4106_CR9","doi-asserted-by":"crossref","DOI":"10.1002\/alz.042909","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard, C. et al. Liraglutide and semaglutide: pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. Alzheimers Dement. 16, e042909 (2020).","journal-title":"Alzheimers Dement."},{"key":"4106_CR10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl, M. et al. In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front. Aging Neurosci. 8, 108 (2016).","journal-title":"Front. Aging Neurosci."},{"key":"4106_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson, K. T. et al. Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav. Brain Res. 356, 271\u2013278 (2019).","journal-title":"Behav. Brain Res."},{"key":"4106_CR12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","volume":"16","author":"RJ Mullins","year":"2019","unstructured":"Mullins, R. J. et al. A pilot study of exenatide actions in Alzheimer\u2019s disease. Curr. Alzheimer Res. 16, 741\u2013752 (2019).","journal-title":"Curr. Alzheimer Res."},{"key":"4106_CR13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 16, 661\u2013673 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"4106_CR14","doi-asserted-by":"publisher","unstructured":"Hogg, E. et al. A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.4212371 (2022).","DOI":"10.2139\/ssrn.4212371"},{"key":"4106_CR15","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J. Clin. Invest. 123, 2730\u20132736 (2013).","journal-title":"J. Clin. Invest."},{"key":"4106_CR16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"4106_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J. Parkinsons Dis. 4, 337\u2013344 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"4106_CR18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda, D. et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD Trial. JAMA Neurol. 76, 420\u2013429 (2019).","journal-title":"JAMA Neurol."},{"key":"4106_CR19","unstructured":"Meissner, W. G. et al. Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson\u2019s disease (PD): the LIXIPARK trial (NCT03439943). Mov. Disord. 38, abstr. 94 (2023)."},{"key":"4106_CR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","volume":"245","author":"AF Batista","year":"2018","unstructured":"Batista, A. F. et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J. Pathol. 245, 85\u2013100 (2018).","journal-title":"J. Pathol."},{"key":"4106_CR21","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean, P. L., Parthsarathy, V., Faivre, E. & Holscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 31, 6587\u20136594 (2011).","journal-title":"J. Neurosci."},{"key":"4106_CR22","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/dom.13373","volume":"20","author":"B Cao","year":"2018","unstructured":"Cao, B. et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and network meta-analysis. Diabetes Obes. Metab. 20, 2467\u20132471 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"4106_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. & Friedhoff, L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group. Neurology 50, 136\u2013145 (1998).","journal-title":"Neurology"},{"key":"4106_CR24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582\u2013590 (2020).","journal-title":"Lancet Neurol."},{"key":"4106_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane, S. et al. Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial. J. Prev. Alzheimers Dis. 12, 100016 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"4106_CR26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois, B. et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement. 11, 1041\u20131049 (2015).","journal-title":"Alzheimers Dement."},{"key":"4106_CR27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","volume":"511","author":"M Zhou","year":"2019","unstructured":"Zhou, M. et al. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2. Biochem. Biophys. Res. Commun. 511, 154\u2013160 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"4106_CR28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hbm.23494","volume":"38","author":"RJ Mullins","year":"2017","unstructured":"Mullins, R. J., Mustapic, M., Goetzl, E. J. & Kapogiannis, D. Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer\u2019s disease. Hum. Brain Mapp. 38, 1933\u20131940 (2017).","journal-title":"Hum. Brain Mapp."},{"key":"4106_CR29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2017.00118","volume":"9","author":"RJ Mullins","year":"2017","unstructured":"Mullins, R. J., Diehl, T. C., Chia, C. W. & Kapogiannis, D. Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer\u2019s disease. Front. Aging Neurosci. 9, 118 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"4106_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt.13.73","volume":"4","author":"K Talbot","year":"2014","unstructured":"Talbot, K. Brain insulin resistance in Alzheimer\u2019s disease and its potential treatment with GLP-1 analogs. Neurodegener. Dis. Manag. 4, 31\u201340 (2014).","journal-title":"Neurodegener. Dis. Manag."},{"key":"4106_CR31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","volume":"15","author":"CM Long-Smith","year":"2013","unstructured":"Long-Smith, C. M. et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease. Neuromolecular Med. 15, 102\u2013114 (2013).","journal-title":"Neuromolecular Med."},{"key":"4106_CR32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s13311-019-00755-y","volume":"16","author":"JC Ryu","year":"2019","unstructured":"Ryu, J. C., Zimmer, E. R., Rosa-Neto, P. & Yoon, S. O. Consequences of metabolic disruption in Alzheimer\u2019s disease pathology. Neurotherapeutics 16, 600\u2013610 (2019).","journal-title":"Neurotherapeutics"},{"key":"4106_CR33","doi-asserted-by":"crossref","unstructured":"Paladugu, L. et al. Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer\u2019s disease. Int. J. Mol. Sci. 22, 860 (2021).","DOI":"10.3390\/ijms22020860"},{"key":"4106_CR34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","volume":"17","author":"F Sun","year":"2015","unstructured":"Sun, F. et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol. Ther. 17, 35\u201342 (2015).","journal-title":"Diabetes Technol. Ther."},{"key":"4106_CR35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/jnc.13169","volume":"135","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 135, 1203\u20131217 (2015).","journal-title":"J. Neurochem."},{"key":"4106_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella, G. D. et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials 20, 191 (2019).","journal-title":"Trials"},{"key":"4106_CR37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"OM Farr","year":"2016","unstructured":"Farr, O. M. et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 59, 954\u2013965 (2016).","journal-title":"Diabetologia"},{"key":"4106_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","volume":"76 Pt A","author":"PL McClean","year":"2014","unstructured":"McClean, P. L. & Holscher, C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease. Neuropharmacology 76 Pt A, 57\u201367 (2014).","journal-title":"Neuropharmacology"},{"key":"4106_CR39","doi-asserted-by":"crossref","unstructured":"Jantrapirom, S. et al. Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int. J. Mol. Sci. 21, 1725 (2020).","DOI":"10.3390\/ijms21051725"},{"key":"4106_CR40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/brain\/123.2.340","volume":"123","author":"MT Hu","year":"2000","unstructured":"Hu, M. T. et al. Cortical dysfunction in non-demented Parkinson\u2019s disease patients: a combined 31P-MRS and 18FDG-PET study. Brain 123, 340\u2013352 (2000).","journal-title":"Brain"},{"key":"4106_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/jcbfm.1993.5","volume":"13","author":"VJ Cunningham","year":"1993","unstructured":"Cunningham, V. J. & Jones, T. Spectral analysis of dynamic PET studies. J. Cereb. Blood Flow Metab. 13, 15\u201323 (1993).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"4106_CR42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968\u2013980 (2006).","journal-title":"Neuroimage"},{"key":"4106_CR43","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs, R. C. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11, S13\u2013S21 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"4106_CR44","first-page":"327","volume":"11","author":"JE Harrison","year":"2007","unstructured":"Harrison, J. E. Measuring cognitive change in Alzheimer\u2019s disease clinical drug trials. J. Nutr. Health Aging 11, 327\u2013329 (2007).","journal-title":"J. Nutr. Health Aging"},{"key":"4106_CR45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1742-4658.2008.06836.x","volume":"276","author":"A Lord","year":"2009","unstructured":"Lord, A. et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer\u2019s disease transgenic mice. FEBS J. 276, 995\u20131006 (2009).","journal-title":"FEBS J."},{"key":"4106_CR46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2010-1390","volume":"20","author":"NG Faux","year":"2010","unstructured":"Faux, N. G. et al. PBT2 rapidly improves cognition in Alzheimer\u2019s disease: additional phase II analyses. J. Alzheimers Dis. 20, 509\u2013516 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"4106_CR47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32, 1207\u20131218 (2011).","journal-title":"Neurobiol. Aging"},{"key":"4106_CR48","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/sim.1981","volume":"24","author":"IR White","year":"2005","unstructured":"White, I. R. & Thompson, S. G. Adjusting for partially missing baseline measurements in randomized trials. Stat. Med. 24, 993\u20131007 (2005).","journal-title":"Stat. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04106-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:03:06Z","timestamp":1769007786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04106-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4106"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04106-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.E. was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). He has also received grants from Alzheimer\u2019s Research UK, the Alzheimer\u2019s Drug Discovery Foundation, Alzheimer\u2019s Society UK, Novo Nordisk, GE Healthcare, AstraZeneca, Pfizer, Eli Lilly and Piramal Life Sciences. He has received speaker fees from Novo Nordisk, Pfizer, Nordea and Piramal Life Sciences. He has received educational and research grants from GE Healthcare, Novo Nordisk, Piramal Life Sciences\/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He was an external consultant to Novo Nordisk and has participated in their Scientific Advisory Board. He is a consultant to Roche, Pfizer and Biohaven. He is the director of Edison Health Sciences Ltd and Edison Sciences Limited. He is a member of the Scientific Advisory Board of CytoDyn and holds shares in CytoDyn. J. Harrison reports receipt of personal fees in the past 2\u2009years from Actinogen, AlzeCure, Aptinyx, AstraZeneca, Athira Pharma, Axoltis, Axon Neuroscience, Bial Biotech, Biogen Idec, Boehringer Ingelheim, Brands2Life, Cerecin, Cognito, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EIP Pharma, Eisai, GfHEU, Heptares, Impact, Ki Elements, LSP Operations, Lundbeck, Lysosomal Therapeutics, MyCognition, Neurotrack, the National Health Service, Novartis, Novo Nordisk, Nutricia, Probiodrug, Prothena, Recognify, Regeneron, reMYND, Roche, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics and Winterlight Labs. Additionally, he holds stock options in Neurotrack and is a joint holder of patents with MyCognition, Ltd. B.R.U.\u02bcs position is partially funded by a donation from Gnodde Goldman Sachs Giving. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}